Abbott withdraws diet pill in US, Canada

Oct 08, 2010 By MATTHEW PERRONE , AP Health Writer

(AP) -- Abbott Laboratories said Friday it will withdraw its diet pill Meridia in the U.S. and Canada, almost a year after studies showed the drug increases the risk of heart attack and stroke in patients with a history of heart disease.

Food and Drug Administration scientists said they requested the withdrawal because the drug's risks were not justified compared with "the very modest weight loss that people achieve on this drug."

"Physicians are advised to stop prescribing Meridia to their patients and patients should stop taking this medication," Dr. John Jenkins, the FDA's director for , said in a statement.

Earlier in the day, Health Canada, the nation's health department, announced that Abbott would voluntarily pull the drug from the market there. Meridia has been available in both countries for more than a decade.

European regulators pulled the product off the market in January after a study showed that patients who had had an 11 percent chance of heart attacks or stroke while taking the drug compared with a 10 percent risk for those not taking it.

Regulators in the U.S. and Canada said they based their decisions on the same data.

Meridia is not widely used in the U.S., with a steep decline in prescriptions in recent years. About 283,000 prescriptions for it were filled last year, just more than half the number in 2005. The typical patient stays on the drug for about 50 days, according to FDA figures. Eighty percent of users are middle-aged women.

North Chicago-based Abbott said it still believes its drug has a positive risk-benefit profile, but agreed to comply with the FDA's request.

Last month a panel of advisers delivered a split vote of 8-8 on whether to allow continued marketing of Meridia. The FDA is not required to follow the advice of the group, though it often does.

Explore further: EU regulator: Morning-after pill OK for all women

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Health Canada warns against Meridia

Oct 16, 2007

Health Canada issued a warning for doctors not to prescribe the weight loss drug Meridia to people who may be at risk of serious heart-related side effects.

Diet drugs face tough test before FDA

Sep 17, 2010

There has never been a magic prescription to help millions of obese Americans lose weight. Whether one is any closer to reality is now under scrutiny.

US restricts, EU bans controversial diabetes pill (Update)

Sep 23, 2010

(AP) -- European regulators ordered the diabetes drug Avandia off the market and the Food and Drug Administration placed stringent restrictions on its use in the United States, saying heart attack risks associated with the ...

FDA panel: Diabetes drug should stay on market

Jul 14, 2010

(AP) -- A majority of federal health experts voted Wednesday to keep the controversial diabetes pill Avandia on the market despite evidence that it increases the risk of heart attack.

FDA confirms benefits of Crestor in more patients

Dec 11, 2009

(AP) -- Federal scientists say AstraZeneca's cholesterol pill Crestor lowers the risk of heart attack, death and stroke in patients without a history of heart disease, though some safety concerns remain.

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

3 hours ago

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

3 hours ago

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

4 hours ago

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

4 hours ago

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

22 hours ago

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments : 0